Adage Capital Partners Gp, L.L.C. Avadel Pharmaceuticals PLC Transaction History

Adage Capital Partners Gp, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.55 - $17.22 $21.2 Million - $29 Million	1,685,983 Added 749.33%	1,910,983 $32.3 Million
Q4 2023 Feb 14, 2024	SELL	$9.64 - $14.59 $14.5 Million - $21.9 Million	-1,500,000 Reduced 86.96%	225,000 $3.18 Million
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $9.84 Million - $15.3 Million	-955,000 Reduced 35.63%	1,725,000 $17.8 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $22.7 Million - $44.2 Million	2,680,000 New	2,680,000 $44.2 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.